Logo

ViiV Healthcare Initiates CUSTOMIZE Study of Dual-Drug Injectable Regimen for the Treatment of HIV

Share this

ViiV Healthcare Initiates CUSTOMIZE Study of Dual-Drug Injectable Regimen for the Treatment of HIV

Shots:

  • The CUSTOMIZE study will evaluate the two-drug regimen consisting ViiV’s Cabotegravir and Janssen’s Edurant (rilpivirine) in patients with HIV with suppressed viral load and no resistance to cabotegravir or rilpivirine
  • In Apr’2019- the US FDA has accepted NDA filing of long-acting dual-drug injectable regimen and has granted PR to NDA with its expected PDUFA date as Dec 29- 2019
  • Edurant is an antiretroviral therapy indicated to treat HIV-1 in patients aged ≥ 12 yrs. Cabotegravir is an investigational therapy- being evaluated as an oral therapy & LA injectable for the treatment & prevention of HIV infection

Click here to read full press release/ article | Ref: GSK | Image: Twitter


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Related News/Articles

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions